Prescribing Information LYNPARZA (olaparib) United Kingdom

This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk

Patient case

study hub

Patient identification flowchart

Explore the patient case studies below to understand individual treatment journeys and help inform your treatment decision-making

Do any of these cases share similarities with patients in your clinical practice? Review whether these patients reflect individuals in your care who may be eligible for LYNPARZA.

All materials for healthcare professionals are intended to be viewed online and not downloaded or printed.

Joe*

Family history of prostate cancer and has progressed whilst receiving ADT and ARPI

CLICK HERE

Paul*

Progressed whilst receiving docetaxel-based triplet therapy

CLICK HERE

Ralph*

Progressed whilst receiving ADT and radiotherapy and lives with his daughter and son-in-law

CLICK HERE

Peter*

Discontinued ARPI > 12 months prior due to AEs

CLICK HERE

Juan*

Progressed whilst receiving ADT monotherapy and has had to stop work due to symptoms

CLICK HERE

Keith*

Progressed whilst receiving ADT and docetaxel and is a carer for his wife

CLICK HERE

*These patient case studies are fictional but based on real-world experiences.

Review the patient identification flowchart below for a stepwise approach that you can apply when considering if your patients are eligible for LYNPARZA

Your patient may still be eligible for LYNPARZA combination therapy if they have previously received an ARPI in the hormone-sensitive setting >12 months prior, without progression at the time of ARPI discontinuation^2†

A hard-copy version of this flowchart is available. Speak to your Oncology Account Manager to request this.

^†Patients may still be eligible for LYNPARZA combination therapy if they received an ARPI in the hormone-sensitive setting and stopped >12 months prior, without PSA, clinical or radiological disease progression at the time of ARPI discontinuation OR if they commenced an alternative ARPI (with a PARPi) for the same indication and discontinued treatment because of intolerance in the absence of disease progression. Eligibility for LYNPARZA monotherapy requires that patients have progressed following an ARPI.²

^‡Including a documented germline and/or somatic deleterious or suspected deleterious BRCA1/2m.¹

^§Patients may still be eligible for LYNPARZA combination therapy if they received chemotherapy in the hormone-sensitive setting.²

^#Patients may still be eligible for LYNPARZA combination therapy if an alternative PARPi with an ARPI was commenced but discontinued due to a lack of tolerance, despite dose reductions, in the absence of disease progression.²

Please refer to the SmPC and Blueteq criteria for full details on eligibility requirements.
Please refer to the SmPC for further information to minimise the risks associated with the use of the medicine before making any prescribing decisions.

Want to learn more about LYNPARZA?

ADT=androgen deprivation therapy; AE=adverse event; ARPI=androgen receptor pathway inhibitor; BRCA1/2m=breast cancer susceptibility gene 1/2 mutation; ECOG PS=Eastern Cooperative Oncology Group Performance Status; mCRPC=metastatic castration-resistant prostate cancer; PARPi=poly ADP (adenosine diphosphate) ribose polymerase inhibitor; PSA=prostate-specific antigen; SmPC=Summary of Product Characteristics.

LYNPARZA (olaparib). Summary of Product Characteristics.
NHS. National Cancer Drugs Fund List. Available at: https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/. Accessed July 2026.

GB-75792 | DOP: July 2026

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.

This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Cookie Policy

Patient case study hub

Explore the patient case studies below to understand individual treatment journeys and help inform your treatment decision-making

Do any of these cases share similarities with patients in your clinical practice? Review whether these patients reflect individuals in your care who may be eligible for LYNPARZA.

Joe*

Paul*

Ralph*

Peter*

Juan*

Keith*

*These patient case studies are fictional but based on real-world experiences.

Review the patient identification flowchart below for a stepwise approach that you can apply when considering if your patients are eligible for LYNPARZA

Your patient may still be eligible for LYNPARZA combination therapy if they have previously received an ARPI in the hormone-sensitive setting >12 months prior, without progression at the time of ARPI discontinuation2†

Want to learn more about LYNPARZA?

Abbreviations and References

These Lynparza website pages were funded and produced by AstraZeneca UK and MSD UK.

Enhance your knowledge, stay informed

Be the first to know. Hear about events, products and ways to support your patients.

Thank you. We will be in touch

Patient case

study hub

Your patient may still be eligible for LYNPARZA combination therapy if they have previously received an ARPI in the hormone-sensitive setting >12 months prior, without progression at the time of ARPI discontinuation^2†